117 related articles for article (PubMed ID: 28282887)
1. New Insights in Thrombin Inhibition Structure-Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin.
Mourier PA; Guichard OY; Herman F; Sizun P; Viskov C
Molecules; 2017 Mar; 22(3):. PubMed ID: 28282887
[TBL] [Abstract][Full Text] [Related]
2. Isolation of a pure octadecasaccharide with antithrombin activity from an ultra-low-molecular-weight heparin.
Mourier PA; Guichard OY; Herman F; Viskov C
Anal Biochem; 2014 May; 453():7-15. PubMed ID: 24561026
[TBL] [Abstract][Full Text] [Related]
3. Thrombin-inhibitory activity of whale heparin oligosaccharides.
Ototani N; Kodama C; Kikuchi M; Yosizawa Z
J Biochem; 1984 Dec; 96(6):1695-703. PubMed ID: 6530392
[TBL] [Abstract][Full Text] [Related]
4. Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin.
Olson ST; Swanson R; Raub-Segall E; Bedsted T; Sadri M; Petitou M; Hérault JP; Herbert JM; Björk I
Thromb Haemost; 2004 Nov; 92(5):929-39. PubMed ID: 15543318
[TBL] [Abstract][Full Text] [Related]
5. Structural features of low-molecular-weight heparins affecting their affinity to antithrombin.
Bisio A; Vecchietti D; Citterio L; Guerrini M; Raman R; Bertini S; Eisele G; Naggi A; Sasisekharan R; Torri G
Thromb Haemost; 2009 Nov; 102(5):865-73. PubMed ID: 19888521
[TBL] [Abstract][Full Text] [Related]
6. Effect of new synthetic heparin mimetics on whole blood thrombin generation in vivo and in vitro in rats.
Hérault JP; Bernat A; Gaich C; Herbert M
Thromb Haemost; 2002 Feb; 87(2):238-44. PubMed ID: 11858483
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of thrombin-inhibiting heparin mimetics without side effects.
Petitou M; Hérault JP; Bernat A; Driguez PA; Duchaussoy P; Lormeau JC; Herbert JM
Nature; 1999 Apr; 398(6726):417-22. PubMed ID: 10201371
[TBL] [Abstract][Full Text] [Related]
8. Analytical comparison of a US generic enoxaparin with the originator product: The focus on comparative assessment of antithrombin-binding components.
Mourier PAJ; Herman F; Sizun P; Viskov C
J Pharm Biomed Anal; 2016 Sep; 129():542-550. PubMed ID: 27497655
[TBL] [Abstract][Full Text] [Related]
9. Antithrombin-binding octasaccharides and role of extensions of the active pentasaccharide sequence in the specificity and strength of interaction. Evidence for very high affinity induced by an unusual glucuronic acid residue.
Guerrini M; Guglieri S; Casu B; Torri G; Mourier P; Boudier C; Viskov C
J Biol Chem; 2008 Sep; 283(39):26662-75. PubMed ID: 18640975
[TBL] [Abstract][Full Text] [Related]
10. Effects on molecular conformation and anticoagulant activities of 1,6-anhydrosugars at the reducing terminal of antithrombin-binding octasaccharides isolated from low-molecular-weight heparin enoxaparin.
Guerrini M; Elli S; Gaudesi D; Torri G; Casu B; Mourier P; Herman F; Boudier C; Lorenz M; Viskov C
J Med Chem; 2010 Nov; 53(22):8030-40. PubMed ID: 21028827
[TBL] [Abstract][Full Text] [Related]
11. Effect of low molecular weight heparin preparations on the inhibition of thrombin by heparin cofactor II.
Tollefsen DM; Sugimori T; Maimone MM
Semin Thromb Hemost; 1990 Oct; 16 Suppl():66-70. PubMed ID: 1962908
[TBL] [Abstract][Full Text] [Related]
12. Oligosaccharide mapping of low molecular weight heparins: structure and activity differences.
Linhardt RJ; Loganathan D; al-Hakim A; Wang HM; Walenga JM; Hoppensteadt D; Fareed J
J Med Chem; 1990 Jun; 33(6):1639-45. PubMed ID: 2160537
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of low-molecular-weight heparin reversal by platelet factor 4.
Fiore MM; Mackie IM
Thromb Res; 2009 May; 124(1):149-55. PubMed ID: 19195682
[TBL] [Abstract][Full Text] [Related]
14. The role of Arg46 and Arg47 of antithrombin in heparin binding.
Arocas V; Bock SC; Olson ST; Björk I
Biochemistry; 1999 Aug; 38(31):10196-204. PubMed ID: 10433728
[TBL] [Abstract][Full Text] [Related]
15. Comparative inhibition of extrinsic and intrinsic thrombin generation by standard heparin, a low molecular weight heparin and the synthetic ATIII-binding pentasaccharide.
Lormeau JC; Herault JP
Thromb Haemost; 1993 Feb; 69(2):152-6, 176. PubMed ID: 8384381
[TBL] [Abstract][Full Text] [Related]
16. Ion exchange chromatographic separation and isolation of oligosaccharides of intact low-molecular-weight heparin for the determination of their anticoagulant and anti-inflammatory properties.
Shastri MD; Johns C; Hutchinson JP; Khandagale M; Patel RP
Anal Bioanal Chem; 2013 Jul; 405(18):6043-52. PubMed ID: 23712644
[TBL] [Abstract][Full Text] [Related]
17. On the relationship between molecular mass and anticoagulant activity in a low molecular weight heparin (enoxaparin).
Bendetowicz AV; Pacaud E; Béguin S; Uzan A; Hemker HC
Thromb Haemost; 1992 May; 67(5):556-62. PubMed ID: 1325683
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
Bendetowicz AV; Béguin S; Caplain H; Hemker HC
Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
[TBL] [Abstract][Full Text] [Related]
19. [Anticoagulant activity of low-molecular-weight heparins obtained using a hydrolase complex].
Drozd NN; Tolstenkov AS; Bannikova GE; Miftakhova NT; Lapikova ES; Makarov VA; Varlamov VP
Eksp Klin Farmakol; 2007; 70(6):19-24. PubMed ID: 18318190
[TBL] [Abstract][Full Text] [Related]
20. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile.
Petitou M; Nancy-Portebois V; Dubreucq G; Motte V; Meuleman D; de Kort M; van Boeckel CA; Vogel GM; Wisse JA
Thromb Haemost; 2009 Nov; 102(5):804-10. PubMed ID: 19888512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
